Clinical Trial Update: A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH ) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ATG 008 (dual mTORC1/2 inhibitor) or ATG-010 (selective exportin 1 inhibitor) in combination with chemotherapy for relapsed/metastatic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Endometrial Cancer
• Ovarian Cancer

Drugs mentioned

• ATG 008 (dual mTORC1/2 inhibitor)
• ATG-010

Snippet

Sponsor: Qi Zhou | Conditions: 1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical Cancer | Phase 2 | Status: UNKNOWN